Ramanath Rao, MD
Cardiology · Zephyrhills, FLNPI 1780791251
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 222 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations.
Across 222 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$627
- Novartis$465
- Johnson & Johnson$441
- Boehringer Ingelheim$393
- Pfizer$350
- Medtronic$328
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,88999%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 30 | $627 |
| Novartis | 26 | $465 |
| Johnson & Johnson | 17 | $441 |
| Boehringer Ingelheim | 17 | $393 |
| Pfizer | 18 | $350 |
| Medtronic(2 entities) | 16 | $328 |
| Abbott | 7 | $277 |
| Boston Scientific | 14 | $272 |
| E.r. Squibb & Sons, L.L.C. | 14 | $248 |
| Merck | 13 | $208 |
| Edwards Lifesciences | 1 | $178 |
| Chiesi USA, Inc. | 7 | $113 |
| Alnylam Pharmaceuticals Inc. | 3 | $96 |
| Kestra Medical Technology Services, Inc. | 1 | $82 |
| Inari Medical, Inc. | 3 | $78 |
| Abiomed | 2 | $71 |
| Impulse Dynamics (USA) Inc. | 1 | $67 |
| AstraZeneca | 4 | $66 |
| Venclose Inc. | 2 | $65 |
| Cvrx, Inc. | 3 | $63 |
| Bayer | 2 | $44 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Angiodynamics, Inc. | 2 | $42 |
| Irhythm Technologies, Inc. | 2 | $40 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Lundbeck LLC | 2 | $37 |
| Stryker | 1 | $31 |
| Coastal Medical Technologies LLC | 1 | $28 |
| Novo Nordisk | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $17 |
| Cashflow Solutions, LLC | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Preventice Services, LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPIEN 3 Ultra RESILIA$178
- MitraClip System$177
- XARELTO$111
- Repatha$106
How this compares
$4,927 in reported general payments places this provider in the 80th percentile of 45 cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 230 | $237,893 |
| XareltoRivaroxaban | 227 | $229,709 |
| JardianceEmpagliflozin | 133 | $148,362 |
| EntrestoSacubitril/Valsartan | 74 | $102,076 |
| Repatha SureclickEvolocumab | 61 | $58,343 |
| Repatha SyringeEvolocumab | 25 | $23,739 |
| Diltiazem 12hr ErDiltiazem Hcl | 26 | $7,416 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 187 | $6,984 |
| FarxigaDapagliflozin Propanediol | 11 | $5,913 |
| Metoprolol Succinate | 547 | $5,486 |
| Midodrine Hcl | 32 | $3,504 |
| Verapamil SrVerapamil Hcl | 14 | $2,791 |
| Atorvastatin Calcium | 232 | $2,638 |
| Ranolazine ErRanolazine | 26 | $2,490 |
| ClopidogrelClopidogrel Bisulfate | 207 | $2,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $350 | $237,893230 claims |
| Johnson & JohnsonXarelto | $441 | $229,709227 claims |
| Boehringer IngelheimJardiance | $393 | $148,362133 claims |
| NovartisEntresto | $465 | $102,07674 claims |
| AstraZenecaFarxiga | $66 | $5,91311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 45 cardiology providers in Florida.
Other cardiology in Zephyrhills
- Shakoor ArainOkeechobee$13K
- Erick CalderonLakewood Ranch$10K
- Melchor GonzalezPalm Coast$8K
- Andres PalomoMiami$7K
- Ariel de la RosaHialeah$7K
- Mayank YadavOrange City$7K
- Lawrence WeinsteinBoynton Beach$5K
- Mohsen RashdanBoca Raton$5K
- Akram ElgendyGainesville$5K
- Thomas MathewsBrooksville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.